Healthcare Leaders Support FTC’s Second Report on PBMs, While PBMs Criticize Findings

On Tuesday, the Federal Trade Commission released its second interim staff report on prescription drug middlemen. The report examines the impact of PBMs (specifically CVS Caremark, Express Scripts and Optum Rx) on specialty generic drugs, highlighting substantial price markups by PBMs on medications for cancer, HIV and other conditions. The post Healthcare Leaders Support FTC’s…

Read More

Inequality aversion and option value

Many policymakers aim to reduce health disparities across groups. In fact, the distributional cost effectiveness analysis (DCEA) approach aims to incorporate treatment value based on the extent to which they reduce inequality. However, what types of inequality are we trying to reduce: ex-post or ex-ante? Ex post inequality means reducing inequality of outcomes at a…

Read More

How Digital Narratives Shape Mental Health Outcomes

By SUHANA MISHRA When discussing treatment outcomes, we usually talk about dosage, adherence, and access. Rarely do we speak about algorithms.  Yet as I began working on a scoping review examining misinformation and disinformation in mental health with a team at the Royal College of Psychiatrists led by Dr. Subodh Dave, I realized that some…

Read More

Poll: After President Trump’s Warning, Many People Are Uncertain About Whether Tylenol Use in Pregnancy Causes Autism; Most Republicans Say It Is Probably or Definitely True

Following the Trump administration’s warning last month that using acetaminophen – the active ingredient in Tylenol – during pregnancy can increase the risk of autism in children, very few (4%) adults say the claim about a causal relationship is “definitely true,” a new KFF Tracking Poll on Health Information and Trust finds.

Read More

Under FDA Clinical Hold, Aardvark Therapeutics Seeks Path Forward for Metabolic Drug

The full FDA clinical hold formally halts all tests of Aardvark Therapeutics’ drug for Prader-Willi syndrome, a rare inherited metabolic disorder that leads to excessive eating. Earlier this year, Aardvark voluntarily paused all tests of its small molecule after a cardiovascular problem emerged in a healthy volunteer. The post Under FDA Clinical Hold, Aardvark Therapeutics…

Read More